CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

CTMX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

CytomX Therapeutics, Inc.NASDAQ: CTMX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 97.6%

Gross margin was 97.6% in Q1 FY2026, down 2.4 pp from a year earlier. On a trailing-twelve-month basis it was 99.3%, down 0.7 pp year over year. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
97.6%-2.4 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMMar 2026
99.3%-0.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.4 pp——
1 year+0.0 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How CTMX compares with its peers on the latest reported figures

  • CTMX's LTM Mar 2026 gross margin of 99.3% is the 2nd highest of the 10 companies compared; the peer median is 69.9%.
  • Its year-over-year change of -0.7 pp is the 5th highest of 8, against a peer median of +1.4 pp.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of +2.5 pp.
CTMX Competitors Peer median
Gross Margin for CTMX and competitors
Company Period LTM level YoY 3-year change
PYXSPyxis Oncology, Inc.LTM Mar 202699.8% ——
CTMXCytomX Therapeutics, Inc.LTM Mar 202699.3% -0.7 pp+0.0 pp
STROSutro Biopharma, Inc.LTM Mar 202698.7% +1.4 pp+5.1 pp
ADCTADC Therapeutics S.A.LTM Mar 202690.7% -2.0 pp-7.9 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
ZYMEZymeworks Inc.LTM Sep 202668.6% -31.4 pp+0.0 pp
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
ADAGAdagene Inc.LTM Jun 2024-14.6% —+0.0 pp
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-662.5% +5797.5 pp+3489.9 pp
VRXAVeraxa Biotech Holding AG—— ——
Peer median (excluding CTMX) 69.9%+1.4 pp+2.5 pp

Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.31M53.16M101.21M138.1M76.2M
Cost of Revenue00000
Gross Profit37.31M53.16M101.21M138.1M76.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development114.19M111.65M77.68M83.38M68.73M
Selling, General & Admin39.16M42.85M30.02M29.73M29.84M
Operating Expenses153.35M154.5M107.7M113.11M98.57M
Depreciation & Amortization2.71M2.44M2.18M1.77M1.38M
EBITDA(113.16M)(96.87M)5.5M33.86M(15.75M)
EBITDA Margin-303.3%-182.2%5.4%24.5%-20.7%
Operating Income(116.04M)(101.34M)(6.48M)25M(22.36M)
Operating Margin-311.0%-190.6%-6.4%18.1%-29.3%
Interest Income255K1.68M9.84M7.14M5.21M
Interest Expense00000
Other Income / Expenses172K2.02M9.81M7.1M5.23M
Income Before Tax(115.87M)(99.32M)3.32M32.09M(17.13M)
Pre-Tax Margin-310.5%-186.8%3.3%23.2%-22.5%
Income Tax Expense003.89M224K238K
Net Income(115.87M)(99.32M)(569K)31.87M(17.37M)
Net Margin-310.5%-186.8%-0.6%23.1%-22.8%
EPS (Basic)(1.26)(1.48)(0.01)0.38(0.15)
EPS (Diluted)(1.26)(1.48)(0.01)0.38(0.15)
Weighted Avg Shares64.15M65.74M73.81M84.44M137.94M
Weighted Avg Shares (Diluted)64.15M65.74M73.81M84.75M137.94M

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Intrinsic Alpha fair value

Locked

Current Price

$1.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.